Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04534322
Title Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple Myeloma (sEAPort)
Acronym sEAPort
Recruitment Approved for marketing
Gender both
Phase Expanded access
Variant Requirements No
Sponsors Oncopeptides AB
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Highlands Oncology Group Springdale Arkansas 72762 United States Details
Beacon Cancer Care Coeur d'Alene Idaho 83814 United States Details
University of Illinois Cancer Center Chicago Illinois 60612 United States Details
Weill Cornell Medicine - Multiple Myeloma Center New York New York 10065 United States Details
Gabrail Cancer Center Canton Ohio 44718 United States Details
Oregon Health & Science University Portland Oregon 97239 United States Details
Prisma Health Cancer Institute Greenville South Carolina 29605 United States Details
Texas Oncology Dallas Texas 75230 United States Details
Community Cancer Trials of Utah Ogden Utah 84405 United States Details
Virginia Cancer Specialists, PC Fairfax Virginia 22031 United States Details
Northwest Medical Specialties Tacoma Washington 98405 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field